-
E334849-100gEthylhexyl Triazone.
-
E334849-100mgEthylhexyl Triazone.
-
E334849-1gEthylhexyl Triazone.
-
E334849-25gEthylhexyl Triazone.
-
E334849-500gEthylhexyl Triazone.
-
E334849-500mgEthylhexyl Triazone.
-
E334849-5gEthylhexyl Triazone.
-
E651387-10mgEthynylcytidine (ECyD), a nucleoside analog and a potent inhibitor of RNA synthesis , inhibits RNA polymerases I, II and II. Ethynylcytidine has robust antitumor activity in a wide range of models of cancerIn VitroThe IC 50 values of Ethynylcytidine
-
E651387-25mgEthynylcytidine (ECyD), a nucleoside analog and a potent inhibitor of RNA synthesis , inhibits RNA polymerases I, II and II. Ethynylcytidine has robust antitumor activity in a wide range of models of cancerIn VitroThe IC 50 values of Ethynylcytidine
-
E651387-5mgEthynylcytidine (ECyD), a nucleoside analog and a potent inhibitor of RNA synthesis , inhibits RNA polymerases I, II and II. Ethynylcytidine has robust antitumor activity in a wide range of models of cancerIn VitroThe IC 50 values of Ethynylcytidine
-
E656653-1mlEthynylcytidine (ECyD), a nucleoside analog and a potent inhibitor of RNA synthesis , inhibits RNA polymerases I, II and II. Ethynylcytidine has robust antitumor activity in a wide range of models of cancerIn VitroThe IC 50 values of Ethynylcytidine
-
E647504-100mgETP-46321 is a potent and orally bioavailable PI3Kα and PI3Kδ inhibitor with K iapp s of 2.3 and 14.2 nM, respectively.In VitroETP-46321 is selected to be screened against other PI3K isoforms. ETP-46321 is more potent against isoform α (K iapp =2.3